Evidence map›Paper›PMID 33812944›Full record

ArticleJournal of virological methods2021

A novel method for conserved sequence extraction with prospective mutation prediction for SARS-CoV-2 PCR primer design.

Saygın Hüseyin Portakal, Beyza Kanat, Murat Sayan, Burak Berber, Osman Doluca

Open access · greenAbstract read
In one paragraph

Article in Journal of virological methods, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Saygın Hüseyin PortakalIzmir University of Economics, Faculty of Engineering, Department of Biomedical Engineering, Izmir, Turkey.
Beyza KanatIzmir University of Economics, Faculty of Engineering, Department of Biomedical Engineering, Izmir, Turkey.
Murat SayanKocaeli University, Faculty of Medicine, Clinical Laboratory, PCR Unit, Kocaeli, Turkey; Turkish Republic of Northern Cyprus.
Burak BerberEskisehir Technical University, Faculty of Science, Department of Biology, Eskisehir, Turkey.
Osman DolucaIzmir University of Economics, Faculty of Engineering, Department of Biomedical Engineering, Izmir, Turkey. Electronic address: osman.doluca@ieu.edu.tr.
İzmir University of Economics · TREskisehir Technical University · TRKocaeli Üniversitesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While the whole genomic sequence of SARS-CoV-2 had been revealed, it was also demonstrated that the genome of SARS-CoV-2 exhibits identity with the genome of SARS-CoV and MERS-CoV with ratios of 80 % and 50 % respectively. In the light of SARS-CoV-2 infection and mortality data, diagnosis and treatment of COVID-19 came into prominence around the world. As such many RT-PCR kits have been developed by biotechnology scientists. However viruses are fast mutating organisms and in order to increase accuracy, feasibility in long term and avoid the off target results of RT-PCR assays, regions of viral genome with low mutation rate and designing of primers targeting these regions are quite important. In this scope, we are presenting a novel algorithm that could be used for finding low mutation rate regions of SARS-CoV-2 and primers that were designed according to findings from our algorithm in this study.

Indexed as

DNA PrimersMutationAlgorithmsCOVID-19COVID-19 Nucleic Acid TestingHumansProspective StudiesSARS-CoV-2Sequence AlignmentDNA PrimersConserved sequenceCOVID-19EvolutionMutation predictionPhylogeneticsPrimer designProbe designSARS-CoV-2

Identifiers

PMID33812944
PMCPMC8015351
OpenAlexW3147795321

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.